ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1310

Efficacy of Abatacept in Patients with Rheumatoid Arthritis Assessed By MRI Scans of Bilateral Hands

Yuji Kukida1, Akiko Kasahara1, Takahiro Seno1,2, Yu Isoda1, Tomoya Sagawa1, Takuya Inoue1, Naoka Kamio1, Risa Sagawa1, Takashi Kida1, Amane Nakabayashi1, Hidetake Nagahara3, Ken Murakami1, Aihiro Yamamoto1, Satoshi Morita4, Hirotoshi Ito5, Masataka Kohno1 and Yutaka Kawahito1, 1Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Rheumatic Diseases and Joint Function, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 3Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 4Department of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan, 5Department of Radiology, Kajiicho Medical Imaging Center, Kyoto, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Abatacept, MRI, radiography and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Imaging of Rheumatic Diseases Poster II: X-ray, MRI, PET and CT

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Previous radiographic and MRI studies have demonstrated that abatacept (ABT) can inhibit the progression of bone and joint destruction in patients with rheumatoid arthritis (RA), just like other biologic agents. However, the relations between MRI scores and other disease indexes are not well-known. And MRI scans of only single hand have been performed in previous reports. The aim of the present study is to evaluate efficacy of ABT in patients with RA using MRI of bilateral hands and to investigate whether MRI scores are related to SDAI and HAQ scores in comparison with radiographic scores.

Methods:

Thirty-five RA patients who had not been received more than 1 biological agent were included in this study. MRI of bilateral hands was performed at baseline and 12 months of intravenous ABT treatment. MRI images were scored for synovitis (0-42), osteitis (0-138) and bone erosion (0-460) according to the Rheumatoid Arthritis MRI Scoring System. Conventional radiographs of hands and feet were also obtained at baseline and 12 months, and they were scored according to the van der Heijde modified total Sharp scoring system. These scores were read by two independent doctors, who were blinded to clinical data. Clinical assessment was performed at baseline and at 1, 3, 6, 9, 12 months. The primary endpoint was change from baseline in MRI-measured synovitis score (SS), osteitis score (OS) and bone erosion score (ES).

Results:

Thirty-one patients completed this study for 12 months. The mean SS and OS were significantly reduced at 12 months compared with the baseline (SS at baseline/ 12 months: 17.1±7.02/ 11.4±6.24 (p<0.0001), OS: 5.11±8.16/ 1.89±2.47 (p=0.003)). On the other hand, ES showed no change throughout the study (28.2±38.6/ 28.7±39.2 (p=0.380)). At 12 months, 57.1% of patients showed no progression in ES (deltaES≤0) and 63.6% of patients showed no progression in radiographic erosion score. Changes from baseline in SS (deltaSS) and ES (deltaES) were correlated with relative SDAI response (p=0.023/0.021), while radiographic scores were not correlated with SDAI score. SS, OS and ES at 12 months were correlated with HAQ score at 12 months (p=0.038/0.007/0.038), while radiographic scores were not correlated with HAQ score statistically. Patients achieving SDAI remission at 12 months (n=11) showed lower OS at 12 months (p=0.030) and lower deltaES (p=0.004) compared to those who didn’t achieve SDAI remission (n=20), while radiographic scores didn’t show significant differences between two groups. Patients achieving HAQ remission at 12 months (n=17) showed lower OS at 12 months (p=0.015), lower SS at 12 months (p=0.049), lower ES at 12 months (p=0.019) and lower deltaES (p<0.001) compared to those who didn’t achieve HAQ remission (n=13).

Conclusion:

ABT reduced synovitis and osteitis score in MRI of bilateral hands at 12 months. Compared to radiographs, MRI of bilateral hands showed higher correlations with SDAI and HAQ scores.


Disclosure: Y. Kukida, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer and Takeda, 2; A. Kasahara, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer and Takeda, 2; T. Seno, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer and Takeda, 2; Y. Isoda, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; T. Sagawa, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; T. Inoue, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; N. Kamio, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; R. Sagawa, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; T. Kida, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; A. Nakabayashi, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; H. Nagahara, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; K. Murakami, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; A. Yamamoto, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; S. Morita, None; H. Ito, None; M. Kohno, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2; Y. Kawahito, AbbVie, Astellas, Bristol-Myers-Squibb, Chugai, Eisai, Janssen Pharma , Mitsubishi-Tanabe, Pfizer, Takeda, 2,AbbVie, Astellas, Bristol-Meyers, Chugai, Eisai, Janssen Pharma, Mitsubishi-Tanabe, Ono, Pfizer, Takeda, UCB, 8.

To cite this abstract in AMA style:

Kukida Y, Kasahara A, Seno T, Isoda Y, Sagawa T, Inoue T, Kamio N, Sagawa R, Kida T, Nakabayashi A, Nagahara H, Murakami K, Yamamoto A, Morita S, Ito H, Kohno M, Kawahito Y. Efficacy of Abatacept in Patients with Rheumatoid Arthritis Assessed By MRI Scans of Bilateral Hands [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-abatacept-in-patients-with-rheumatoid-arthritis-assessed-by-mri-scans-of-bilateral-hands/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-abatacept-in-patients-with-rheumatoid-arthritis-assessed-by-mri-scans-of-bilateral-hands/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology